Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia, Katowice 40-752, Poland.
World J Gastroenterol. 2024 May 14;30(18):2387-2390. doi: 10.3748/wjg.v30.i18.2387.
Metabolic dysfunction-associated steatotic liver disease (MASLD), once known as non-alcoholic fatty liver disease (NAFLD), represents a spectrum of liver disorders characterized by lipid accumulation within hepatocytes. The redefinition of NAFLD in 2023 marked a significant reposition in terminology, emphasizing a broader understanding of liver steatosis and its associated risks. MASLD is now recognized as a major risk factor for liver cirrhosis, hepatocellular carcinoma, and systemic complications such as cardiovascular diseases or systemic inflammation. Diagnostic challenges arise, particularly in identifying MASLD in lean individuals, necessitating updated diagnostic protocols and investing in non-invasive diagnostic tools. Therapeutically, there is an urgent need for effective treatments targeting MASLD, with emerging pharmacological options focusing on, among others, carbohydrate and lipid metabolism. Additionally, understanding the roles of bile acid metabolism, the microbiome, and dietary interventions in MASLD pathogenesis and management holds promise for innovative therapeutic approaches. There is a strong need to emphasize the importance of collaborative efforts in understanding, diagnosing, and managing MASLD to improve physicians' approaches and patient outcomes.
代谢相关脂肪性肝病（MASLD），曾被称为非酒精性脂肪性肝病（NAFLD），代表了一系列以肝细胞内脂质蓄积为特征的肝脏疾病谱。2023 年对 NAFLD 的重新定义标志着术语的重大重新定位，强调了对肝脏脂肪变性及其相关风险的更广泛理解。MASLD 现在被认为是肝硬化、肝细胞癌以及心血管疾病或全身炎症等系统性并发症的主要危险因素。诊断面临挑战，特别是在识别瘦个体中的 MASLD 时，需要更新诊断方案并投资于非侵入性诊断工具。在治疗方面，迫切需要针对 MASLD 的有效治疗方法，新兴的药物治疗选择侧重于碳水化合物和脂质代谢等方面。此外，了解胆汁酸代谢、微生物组和饮食干预在 MASLD 发病机制和管理中的作用，为创新的治疗方法提供了希望。强烈需要强调在理解、诊断和管理 MASLD 方面开展合作的重要性，以改善医生的方法和患者的结局。
